author-photo

Xiang Qin

Janssen Pharmaceutica

61

Papers

3069

Citations

Citation Trend

Filter By

Papers (40) Sort By

Journal Conference Others

Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-chain Amyloidosis.

2021 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (1)
Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (67)
Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (71)
Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)